Disclaimer: The medications discussed in this article may include compounded preparations from a licensed 503A compounding pharmacy. Compounded medications have not been reviewed or approved by the FDA and are not the same as commercially available FDA-approved products. This content is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Please consult a licensed healthcare provider for personalized clinical guidance.
A patient discontinued TRT at week three. He felt more fatigued than before he started, his mood was inconsistent, and he had some mild water retention. He told me it was not working. When I reviewed his labs and timeline, everything was proceeding exactly as expected. He was three weeks into a therapy that typically takes eight to twelve weeks to produce its full clinical effect.
That experience changed how I onboard every new TRT patient. I now spend significant time before the first injection explaining what the first month actually looks like, what side effects of testosterone injections are expected versus concerning, and why the first-month experience is not representative of what TRT does over time. The pharmacology of testosterone cypionate provides the explanation, and once patients understand it, the early weeks become much easier to tolerate.
The Pharmacokinetics of Testosterone Cypionate
Testosterone cypionate has a specific pharmacokinetic profile that directly predicts when patients feel effects and why the early weeks are variable. After a subcutaneous or intramuscular injection, peak serum testosterone levels are reached at approximately 24 to 48 hours. The half-life of testosterone cypionate is approximately 8 days, meaning the concentration drops by half roughly every eight days after that peak. In a standard once-weekly injection protocol, this creates a cycle: a peak on day one to two, a gradual decline through the week, and a trough just before the next injection.
The trough is clinically relevant for patient experience. Before steady-state levels have been established, typically after three to five injection cycles, there can be a noticeable difference between how patients feel at peak and how they feel at trough. This fluctuation often manifests as variability in energy, mood, and libido across the week. When I explain the pharmacokinetics upfront, patients understand why they feel better on day two than on day seven, and they are far less likely to interpret the trough as treatment failure.
As the protocol progresses and steady-state serum levels are achieved, the peak-to-trough variation becomes more predictable and patients adapt to the rhythm. Some patients benefit from transitioning to twice-weekly smaller injections to flatten this curve, which becomes a clinical conversation when relevant.
Why the First Four to Six Weeks Feel Unpredictable
When testosterone is introduced exogenously, the body undergoes a period of hormonal recalibration beyond the simple pharmacokinetic curve. The enzyme CYP19A1, commonly known as aromatase, converts testosterone to estradiol. Aromatase is expressed primarily in adipose tissue. As testosterone levels rise in the early weeks of therapy, estradiol production increases proportionally. For some patients, this estrogen rise outpaces the downstream adaptation of hormone receptors, producing temporary symptoms including water retention, mood variability, and reduced energy. This typically self-corrects within the first four to six weeks as estrogen stabilizes and receptor sensitivity adjusts.
What I see in patients during this window is sometimes discouragement — a patient hoping for more energy and better mood may feel transiently worse before feeling better. The patient who quit at week three would have felt the full benefit by week eight. Better upfront education on what that window looks like is the most effective intervention.
Hematocrit: The Biology, the Risk, and Why Labs Are Non-Negotiable
Testosterone stimulates the production of erythropoietin (EPO) in the kidneys, the hormone that drives red blood cell production in the bone marrow. As EPO rises, hematocrit increases. This is a normal physiological effect of elevated testosterone, not a pathological one.
The clinical concern arises when hematocrit rises substantially. In clinical research, intramuscular testosterone injections produce a mean hematocrit increase of approximately 4.0 percent. Clinical significance is typically assigned when levels exceed 52 to 54 percent. As hematocrit rises, blood viscosity increases, and with it the theoretical risk of cardiovascular events including deep vein thrombosis. This is why lab monitoring is a required part of the protocol, not optional.
At Precision Telemed, providers monitor hematocrit alongside total testosterone, free testosterone, and estradiol. If hematocrit rises to concerning levels, the management options are dose adjustment, increased injection frequency with smaller individual doses, or therapeutic phlebotomy.
Side Effects of Testosterone Injections: Estrogen Conversion and the Role of Anastrozole
The CYP19A1 aromatase enzyme, expressed primarily in adipose tissue, converts testosterone to estradiol. The rate of this conversion varies meaningfully between individuals, with higher adipose tissue mass generally correlating with greater aromatase activity. When estradiol rises too high during TRT, patients can experience nipple sensitivity or tenderness, water retention, emotional lability, and reduced libido — symptoms caused by excess estrogen, not excess testosterone. This is one of the most common sources of confusion among patients new to TRT.
Anastrozole, an aromatase inhibitor, reduces the rate of testosterone-to-estradiol conversion. The goal is not to suppress estrogen to zero. Estradiol serves important functions in men including maintaining bone density, supporting cardiovascular health, and contributing to libido. The clinical target is to keep estradiol within a physiologically appropriate range, determined through lab monitoring rather than symptoms alone.
Not every patient needs the same anastrozole dose. Low estrogen in men produces its own set of symptoms: joint pain, low libido, depressed mood, and fatigue that mirrors the symptoms of low testosterone itself. A provider who monitors estradiol and adjusts anastrozole based on individual response produces far better outcomes than a fixed-dose approach applied uniformly.
Testicular Atrophy, the HPT Axis, and Fertility
Exogenous testosterone suppresses the hypothalamic-pituitary-testicular (HPT) axis through negative feedback. When the hypothalamus detects adequate circulating testosterone, it reduces GnRH secretion. Lower GnRH means lower LH and FSH from the pituitary. Without LH stimulation, the Leydig cells in the testes dramatically reduce endogenous testosterone production. Without FSH, spermatogenesis is suppressed. Over time, the testes atrophy from disuse, and sperm production may fall significantly with prolonged therapy.
For patients not concerned about fertility, testicular atrophy is typically a manageable cosmetic change rather than a health risk. For patients interested in preserving fertility, this conversation needs to happen before therapy begins. Gonadorelin, a synthetic GnRH analogue, can be administered alongside TRT to maintain LH and FSH secretion and prevent full testicular function suppression. Clomiphene citrate offers an alternative mechanism. Patients who come to me with fertility concerns receive a different protocol structure than those who do not — and that discussion happens before the first injection.
Some patients dealing with overlapping low testosterone and low IGF-1 may benefit from sermorelin alongside TRT. For a full explanation of how the growth hormone and testosterone axes interact, see Does Sermorelin Increase Testosterone?.
Long-Term Outcomes: What the Research Shows
The long-term data on appropriately managed TRT is reassuring. Data published in the European Heart Journal found that patients receiving TRT who normalized their serum testosterone levels had a significantly lower risk of all-cause mortality, myocardial infarction, and stroke compared to patients whose testosterone levels did not normalize with therapy (Sharma et al., Eur Heart J 2015, PMID 26048144). The key phrase is “normalized” — the protective association was observed in patients whose testosterone was brought into a normal physiological range with monitoring and dose management, not supraphysiologic levels.
The thirty-day window that first-month patients experience is an adjustment phase. The cardiovascular and metabolic benefits described in the literature are cumulative and develop over months.
Injection Site Management
Testosterone cypionate is an oil-based formulation. Cold oil is more viscous and more uncomfortable to inject. Holding the vial in the hand or warming it briefly under warm water before drawing reduces injection resistance substantially. Rotating between multiple sites — the lateral quadriceps, ventrogluteal area, and deltoid — prevents tissue buildup and microfibrosis at any single location. Patients who inject consistently at the same site often develop soreness and firmness that is entirely preventable with rotation.
FAQ
Q: How long before TRT produces noticeable benefits? Energy and mood improvements often begin within two to four weeks. Libido improvements are typically more evident at weeks six to twelve. Full body composition changes generally require three to six months of consistent therapy. The first month is an adjustment and calibration period, not the full clinical experience.
Q: Is long-term TRT safe? Long-term TRT is considered safe for appropriately selected patients who are monitored regularly — ongoing monitoring of hematocrit, testosterone levels, estradiol, PSA (in men over 40), and general metabolic panels. Patients managed with appropriate lab follow-up and dose adjustment have a well-established safety profile in the clinical literature.
Q: Why is hematocrit monitored so closely? Testosterone stimulates EPO production in the kidneys, which increases red blood cell production and raises hematocrit. When hematocrit rises significantly, it increases blood viscosity and can elevate cardiovascular risk. Monitoring allows providers to detect and manage this before it becomes a clinical concern.
Q: What is anastrozole and why is it included? Anastrozole is an aromatase inhibitor that reduces the CYP19A1-mediated conversion of testosterone to estradiol. When estrogen rises too high during TRT, patients can experience water retention, mood changes, nipple sensitivity, and reduced libido. Including anastrozole in the protocol helps manage this proactively. Dosing is individualized based on labs and symptom response.
Q: Can fertility be preserved while on TRT? Yes, with additional medications. Gonadorelin and clomiphene citrate are two options that support continued pituitary and testicular signaling during testosterone therapy. Patients for whom fertility preservation is a priority should discuss this with their provider before starting therapy so the protocol can be structured accordingly from the beginning.
Q: What should patients do if they experience side effects in the first few weeks? Most early side effects — including injection site reactions, mild water retention, mood variability, and fatigue — are part of the adjustment period and resolve within four to six weeks. Precision Telemed providers are available through the platform for follow-up. Discontinuing therapy based on the first two to three weeks alone, without a provider consultation, forfeits the adaptation progress already underway.
References
- Bhasin S et al. Testosterone Therapy in Men with Hypogonadism. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PubMed
- Hackett G et al. Testosterone replacement therapy: practical aspects. Ther Adv Urol. 2015;7(4):198-209. PubMed
- Sharma R et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36(40):2706-2715. PubMed
- Snyder PJ et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. PubMed
To speak with one of our licensed providers about whether this is right for you, visit precisiontelemed.com.
This article is for educational purposes only and does not constitute medical advice or establish a provider-patient relationship. Compounded medications have not been reviewed by the FDA and are not the same as commercially available FDA-approved products. Please consult your healthcare provider.